JP2018527886A - 転移性疾患の予測的遺伝子シグネチャー - Google Patents

転移性疾患の予測的遺伝子シグネチャー Download PDF

Info

Publication number
JP2018527886A
JP2018527886A JP2017565108A JP2017565108A JP2018527886A JP 2018527886 A JP2018527886 A JP 2018527886A JP 2017565108 A JP2017565108 A JP 2017565108A JP 2017565108 A JP2017565108 A JP 2017565108A JP 2018527886 A JP2018527886 A JP 2018527886A
Authority
JP
Japan
Prior art keywords
cancer
gene
subject
sample
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017565108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527886A5 (enExample
Inventor
スティーブン・ウォーカー
ローラ・ヒル
アンドリーナ・マッキャビガン
シニード・ドネガン
ティモシー・デイビソン
リチャード・ケネディ
デニス・ポール・ハーキン
ベサニー・プライス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Diagnostics Ltd
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of JP2018527886A publication Critical patent/JP2018527886A/ja
Publication of JP2018527886A5 publication Critical patent/JP2018527886A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017565108A 2015-06-17 2016-06-17 転移性疾患の予測的遺伝子シグネチャー Pending JP2018527886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease
GB1510684.2 2015-06-17
PCT/GB2016/051825 WO2016203262A2 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease

Publications (2)

Publication Number Publication Date
JP2018527886A true JP2018527886A (ja) 2018-09-27
JP2018527886A5 JP2018527886A5 (enExample) 2019-07-04

Family

ID=53784091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565108A Pending JP2018527886A (ja) 2015-06-17 2016-06-17 転移性疾患の予測的遺伝子シグネチャー

Country Status (8)

Country Link
US (1) US20210254166A1 (enExample)
EP (1) EP3310927B1 (enExample)
JP (1) JP2018527886A (enExample)
CN (1) CN108513587A (enExample)
CA (1) CA2989388A1 (enExample)
GB (1) GB201510684D0 (enExample)
HK (1) HK1246367A1 (enExample)
WO (1) WO2016203262A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023511237A (ja) * 2020-01-21 2023-03-16 ジェニアリス インコーポレイテッド 分子バイオマーカーデータセット全体にわたる予測シグネチャの堅牢性および転用可能性の評価

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11341138B2 (en) * 2017-12-06 2022-05-24 International Business Machines Corporation Method and system for query performance prediction
GB201901439D0 (en) * 2019-02-01 2019-03-27 Univ London Method of predicting survival rates for cancer patients
GB201903015D0 (en) * 2019-03-08 2019-04-17 Univ Edinburgh Macrophage expression in breast cancer
GB201903014D0 (en) * 2019-03-06 2019-04-17 Univ Edinburgh Macrophage markers in cancer
CA3174199A1 (en) 2020-04-09 2021-10-14 Ashraf Hafez Predicting likelihood and site of metastasis from patient records
TW202216996A (zh) 2020-06-29 2022-05-01 美商Ionis製藥公司 調節ｐｌｐ１之化合物及方法
WO2022086914A1 (en) * 2020-10-19 2022-04-28 Temple University - Of The Commonwealth System Of Higher Education Genetic approach to suppress coronaviruses
CN117741155A (zh) * 2023-11-21 2024-03-22 中国药科大学 Abcc4蛋白用于制备前列腺癌诊断试剂盒的用途
CN120197220B (zh) * 2025-05-23 2025-08-01 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506033A (ja) * 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
JP2013512000A (ja) * 2009-12-01 2013-04-11 コンペンディア バイオサイエンス， インコーポレイテッド 癌の分類
JP2014513730A (ja) * 2011-05-17 2014-06-05 武田薬品工業株式会社 癌を治療するための薬学的組成物および方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
IE72468B1 (en) 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
ZA899593B (en) 1988-12-16 1990-09-26 Siska Diagnostics Inc Self-sustained,sequence replication system
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
WO2004085621A2 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
US20140018249A1 (en) * 2006-07-26 2014-01-16 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
NZ582941A (en) 2007-08-13 2012-05-25 Almac Diagnostics Ltd A 3' -based sequencing approach for microarray manufacture
DK2376215T3 (en) * 2008-12-11 2019-01-28 Univ California FILTER CONE
WO2014012176A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005506033A (ja) * 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
JP2013512000A (ja) * 2009-12-01 2013-04-11 コンペンディア バイオサイエンス， インコーポレイテッド 癌の分類
JP2014513730A (ja) * 2011-05-17 2014-06-05 武田薬品工業株式会社 癌を治療するための薬学的組成物および方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023511237A (ja) * 2020-01-21 2023-03-16 ジェニアリス インコーポレイテッド 分子バイオマーカーデータセット全体にわたる予測シグネチャの堅牢性および転用可能性の評価
JP7741104B2 (ja) 2020-01-21 2025-09-17 ジェニアリス インコーポレイテッド 分子バイオマーカーデータセット全体にわたる予測シグネチャの堅牢性および転用可能性の評価

Also Published As

Publication number Publication date
US20210254166A1 (en) 2021-08-19
HK1246367A1 (zh) 2018-09-07
WO2016203262A2 (en) 2016-12-22
CA2989388A1 (en) 2016-12-22
EP3310927B1 (en) 2021-05-19
EP3310927A2 (en) 2018-04-25
CN108513587A (zh) 2018-09-07
WO2016203262A3 (en) 2017-01-26
GB201510684D0 (en) 2015-08-05

Similar Documents

Publication Publication Date Title
US20240084397A1 (en) Methods and systems for detecting cancer via nucleic acid methylation analysis
EP3080293B1 (en) Prostate cancer classification
EP3310927B1 (en) Gene signatures predictive of metastatic disease
JP6985753B2 (ja) 血漿による胎児または腫瘍のメチロームの非侵襲的決定
US10113201B2 (en) Methods and compositions for diagnosis of glioblastoma or a subtype thereof
CN115667554A (zh) 通过核酸甲基化分析检测结直肠癌的方法和系统
US12545961B2 (en) Method of predicting risk of recurrence of cancer
US20090192045A1 (en) Molecular staging of stage ii and iii colon cancer and prognosis
Smits et al. Molecular biomarkers to guide precision medicine in localized prostate cancer
Montalbo et al. Prognostic value of circulating microRNAs in upper tract urinary carcinoma
Low et al. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer
Jin et al. Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes
WO2017046714A1 (en) Methylation signature in squamous cell carcinoma of head and neck (hnscc) and applications thereof
Goh et al. Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer
US11473131B2 (en) Methods for detecting genomic DNA methylation
WO2026044029A1 (en) Development and use stemness metrics for prostate cancer risk stratification and prognosis
HK40107669A (en) Methods and systems for detecting cancer via nucleic acid methylation analysis
JP2025535077A (ja) 癌の多数の分析物検出のためのシステムおよび方法
WO2020104482A1 (en) Methods for predicting metastatic potential in patients suffering from sdhb-mutated paraganglioma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210209